CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy